111 related articles for article (PubMed ID: 10736422)
1. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF).
Woynarowska BA; Woynarowski JM; Herzig MC; Roberts K; Higdon AL; MacDonald JR
Biochem Pharmacol; 2000 May; 59(10):1217-26. PubMed ID: 10736422
[TBL] [Abstract][Full Text] [Related]
2. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF).
Herzig MC; Arnett B; MacDonald JR; Woynarowski JM
Biochem Pharmacol; 1999 Jul; 58(2):217-25. PubMed ID: 10423161
[TBL] [Abstract][Full Text] [Related]
3. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114).
Woynarowski JM; Napier C; Koester SK; Chen SF; Troyer D; Chapman W; MacDonald JR
Biochem Pharmacol; 1997 Dec; 54(11):1181-93. PubMed ID: 9416969
[TBL] [Abstract][Full Text] [Related]
4. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells.
Woynarowska BA; Roberts K; Woynarowski JM; MacDonald JR; Herman TS
Radiat Res; 2000 Oct; 154(4):429-38. PubMed ID: 11023607
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents.
Kelner MJ; McMorris TC; Estes L; Wang W; Samson KM; Taetle R
Invest New Drugs; 1996; 14(2):161-7. PubMed ID: 8913837
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.
MacDonald JR; Muscoplat CC; Dexter DL; Mangold GL; Chen SF; Kelner MJ; McMorris TC; Von Hoff DD
Cancer Res; 1997 Jan; 57(2):279-83. PubMed ID: 9000568
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent.
Yu X; Erzinger MM; Pietsch KE; Cervoni-Curet FN; Whang J; Niederhuber J; Sturla SJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):426-33. PubMed ID: 22895897
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.
Herzig MC; Trevino AV; Liang H; Salinas R; Waters SJ; MacDonald JR; Woynarowska BA; Woynarowski JM
Biochem Pharmacol; 2003 Feb; 65(4):503-13. PubMed ID: 12566077
[TBL] [Abstract][Full Text] [Related]
10. Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.
Kelner MJ; McMorris TC; Montoya MA; Estes L; Uglik SF; Rutherford M; Samson KM; Bagnell RD; Taetle R
Cancer Chemother Pharmacol; 1999; 44(3):235-40. PubMed ID: 10453725
[TBL] [Abstract][Full Text] [Related]
11. Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
Kelner MJ; McMorris TC; Estes L; Samson KM; Trani NA; MacDonald JR
Leukemia; 2000 Jan; 14(1):136-41. PubMed ID: 10637489
[TBL] [Abstract][Full Text] [Related]
12. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
[TBL] [Abstract][Full Text] [Related]
13. Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug.
McMorris TC
Bioorg Med Chem; 1999 May; 7(5):881-6. PubMed ID: 10400341
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
15. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.
Lim JT; Piazza GA; Han EK; Delohery TM; Li H; Finn TS; Buttyan R; Yamamoto H; Sperl GJ; Brendel K; Gross PH; Pamukcu R; Weinstein IB
Biochem Pharmacol; 1999 Oct; 58(7):1097-107. PubMed ID: 10484067
[TBL] [Abstract][Full Text] [Related]
16. Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells.
Cattaneo-Pangrazzi RM; Schott H; Wunderli-Allenspach H; Derighetti M; Schwendener RA
Biochem Pharmacol; 2000 Dec; 60(12):1887-96. PubMed ID: 11108805
[TBL] [Abstract][Full Text] [Related]
17. Molecular modes of action of artesunate in tumor cell lines.
Efferth T; Sauerbrey A; Olbrich A; Gebhart E; Rauch P; Weber HO; Hengstler JG; Halatsch ME; Volm M; Tew KD; Ross DD; Funk JO
Mol Pharmacol; 2003 Aug; 64(2):382-94. PubMed ID: 12869643
[TBL] [Abstract][Full Text] [Related]
18. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia.
Zhelev Z; Ohba H; Bakalova R; Hadjimitova V; Ishikawa M; Shinohara Y; Baba Y
Cancer Chemother Pharmacol; 2004 Mar; 53(3):267-75. PubMed ID: 14663628
[TBL] [Abstract][Full Text] [Related]
19. Promising new agents for treatment of patients with colorectal cancer.
Von Hoff DD
Semin Oncol; 1998 Oct; 25(5 Suppl 11):47-52. PubMed ID: 9786316
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
